Answers are grounded in this paper and cite their sources.
Efficacy evaluation shows budesonide reduces proteinuria in IgA nephropathy, indicating promising real-world application.
IgA nephropathy (IgAN) is the most common primary glomerulonephritis. Budesonide targets IgAN pathogenesis by inhibiting galactose-deficient IgA1 (Gd-IgA1) production in Peyer's patches. While pivotal trials have confirmed its efficacy in slowing renal function decline and reducing proteinuria, real-world evidence in broader, more heterogeneous patient populations remains scarce.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: